Previous Close | 10.54 |
Open | 10.52 |
Bid | 10.24 x 0 |
Ask | 10.47 x 0 |
Day's Range | 10.15 - 10.65 |
52 Week Range | 9.55 - 20.44 |
Volume | |
Avg. Volume | 4,617 |
Market Cap | 250.396M |
Beta (5Y Monthly) | 0.79 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.87 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.90 |
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...
Profound Medical ( TSE:PRN ) Full Year 2023 Results Key Financial Results Net loss: US$28.6m (flat on FY 2022). US$1.35...